Artelo Biosciences, Inc. (ARTL) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 2 Buy, 2 Hold.
Analysts estimate Earnings Per Share (EPS) of $-11.82 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.02 vs est $-11.82 (beat +91.4%). 2025: actual $-5.47 vs est $-36.33 (beat +84.9%). Analyst accuracy: 0%.
ARTL Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to Artelo Biosciences, Inc. in the past 3 months
EPS Estimates — ARTL
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.02
vs Est –$11.82
▲ 1,062.7% off
2025
Actual –$5.47
vs Est –$36.33
▲ 564.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — ARTL
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
